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The ATP-gated receptor P2X7 (P2X7R) is involved in regulation of cell survival and has been of interest in cancer field. Pancre-
atic ductal adenocarcinoma (PDAC) is a deadly cancer and new markers and therapeutic targets are needed. PDAC is characterized
by a complex tumour microenvironment, which includes cancer and pancreatic stellate cells (PSCs), and potentially high nucleo-
tide/side turnover. Our aim was to determine P2X7R expression and function in human pancreatic cancer cells in vitro as well as
to perform in vivo efficacy study applying P2X7R inhibitor in an orthotopic xenograft mouse model of PDAC. In the in vitro studies
we show that human PDAC cells with luciferase gene (PancTu-1 Luc cells) express high levels of P2X7R protein. Allosteric P2X7R
antagonist AZ10606120 inhibited cell proliferation in basal conditions, indicating that P2X7R was tonically active. Extracellular
ATP and BzATP, to which the P2X7R is more sensitive, further affected cell survival and confirmed complex functionality of P2X7R.
PancTu-1 Luc migration and invasion was reduced by AZ10606120, and it was stimulated by PSCs, but not by PSCs from P2X7-/-
animals. PancTu-1 Luc cells were orthotopically transplanted into nude mice and tumour growth was followed noninvasively by
bioluminescence imaging. AZ10606120-treated mice showed reduced bioluminescence compared to saline-treated mice. Immu-
nohistochemical analysis confirmed P2X7R expression in cancer and PSC cells, and in metaplastic/neoplastic acinar and duct
structures. PSCs number/activity and collagen deposition was reduced in AZ10606120-treated tumours.
Introduction
Pancreatic ductal adenocarcinoma (PDAC) is the most com-
mon form of pancreatic cancer, and with a 5-year survival rate
<5% it ranks as one of the most deadly cancers.1,2 This
extremely poor prognosis is largely attributed to its propensity
for early local invasion and distant metastases and to the
asymptomatic development of the early stage of the pancreatic
cancer.3 Consequently, this type of cancer is often not detected
until it has already disseminated to surrounding or distant
organs and vessels, and therefore most of the current therapies
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are more palliative then curative. New treatment strategies are
therefore desperately needed.4 There are two main theories
about how epithelial cells might drive the tumour development.
In the classical model it has been proposed that pancreatic
ducts undergo a series of pancreatic intraepithelial neoplasias
(PanINs), epithelial to mesenchymal transition (EMT) and pro-
gression to invasive cancer.5 A number of studies support a dif-
ferent model, which proposes that acinar-to-duct metaplasia
can give rise to tubular complexes that may occur in parallel
and/or progress to PDAC.6,7 An important cellular component
in PDAC are pancreatic stellate cells (PSCs) that secrete extra-
cellular matrix (ECM) proteins, such as collagens and laminin,
and contribute to the stiffness and impermeability of these solid
tumours, and thus reduced delivery of chemotherapeutic drugs.
A number of studies document that coexistence of cancer cells
and activated PSCs supports tumour growth and malignancy
both in vitro and in vivomodels.8
One of the general characteristics of cancer cells is a high
metabolic rate and therefore there is a high turnover of intracel-
lular nucleotides/sides. Recently, novel in vivo ATP imaging
probes revealed relative high levels of extracellular ATP at
tumour sites,9 released to the extracellular compartment by
metabolically active cancer cells and dying cells in the tumour
necrotic core. Therefore, ATP-activated receptors, i.e., the puri-
nergic receptors (P2X and P2Y), could be important receptors
regulating both cancer and stromal cell proliferation, apoptosis
and migration.10
One of the cancer-relevant receptors is the P2X7 receptor
(P2X7R). The receptor exists in several splice isoforms (A–J)
and single nucleotide polymorphisms (SNPs) correlate with
several diseases.11,12 The P2X7R is a ligand-gated ion channel
permeable to Ca21, K1 and Na1.13 Following sustained activa-
tion or overstimulation, this receptor forms or facilitates forma-
tion of pores permeable to large molecules that can lead to cell
lysis and death.14,15 In the cancer ﬁeld, P2X7R is believed to
play multiple roles. First, it can be an anti-tumour receptor
inducing cancer cell death.16,17 Second, P2X7R can also be a
procancer receptor, as it supports cancer cell proliferation,
migration and invasion, both in vitro18,19 and in vivo.20 One
explanation is that these seemingly opposite effects depend on
expression/interaction of presumed proapoptotic P2X7A iso-
form and trophic isoform P2X7B.21 Third, P2X7R is involved
in inﬂammation and immune system modulation, which can
potentially affect tumour growth and progression.1,22
Many cancers, such as human breast cancer18 and human
prostate carcinoma,23 show increased expression of P2X7R. In
our recent study, we showed higher expression of P2X7R in
several PDAC cell lines compared to noncancer cells and char-
acterized the in vitro effect on proliferation and migration/
invasion.24 Also, pancreatic stellate cells express P2X7R and in
in vitro conditions inhibition of this receptor decreased cell
proliferation.25
The aim of this study was to determine the role of P2X7R
in the in vivo model of an orthotopic xenograft human
pancreatic cancer. In particular, we wanted to test the effect of
the P2X7R allosteric inhibitor AZ10606120. For this purpose
we have utilized PancTu-1 cell line expressing the luciferase
gene (PancTu-1 Luc) for bioluminescence imaging to follow
tumour development and progression in response to P2X7R
antagonism. Prior to the in vivo study, we validated our
approach in in vitro assays of PancTu-1 Luc cells
by determining P2X7R expression, drugs sensitivity and inter-
play with PSCs. Here, we show that AZ10606120 has a poten-
tial to inﬂuence pancreatic tumour growth and limits ﬁbrosis.
Material and Methods
Cell culture
PancTu-1 cells (established by Dr. M. v. Bulow, Mainz,
Germany), modiﬁed to stably express luciferase (PancTu-1 Luc
cells), were kindly donated by Prof. Dr. Holger Kalthoff
(University Hospital Schleswig-Holstein, Kiel, Germany). Cells
were grown in RPMI-1640 media supplemented with 10% fetal
bovine serum (FBS) (PAA Laboratories; A15-151 Gold). For
the in vitro experiments performed in Copenhagen, 100 U/ml
penicillin and 100 lg/ml streptomycin were added to the
medium. For the in vivo experiments performed in G€ottingen,
cells were grown without antibiotics. The human pancreatic
duct epithelial cell line HPDE6-E6E7 (H6c7) transformed with
HPV16,26 here abbreviated HPDE, was grown as described
earlier.24
RNA isolation, RT-PCR and western blot
RNA isolation, RT-PCR and Western blot were performed as
previously described.24 The primers used to detect human
P2X7 mRNA were: forward primer: 50–CGGTTGTGTCCCG
AGTATCC–30 and reverse primer: 50–CCTGGCAGGATG
TTTCTCGT–30 (284 bp). We performed RT-PCR rather
than Real Time-PCR (qPCR), because it is not possible to
What’s new?
Pancreatic ductal adenocarcinoma (PDAC) is one the most difficult types of cancer to detect and treat, challenges that could
be overcome through the discovery and development of novel markers and therapeutic strategies. Here, the P2X7 receptor,
which regulates cell survival, is shown to also support cell proliferation, migration and invasion in human P2X7R-expressing
PDAC cells. Treatment of orthotopic PDAC tumor-bearing mice with the P2X7R-specific inhibitor, AZ10606120, resulted in
decreased tumor bioluminescence and reductions in pancreatic stellate cells and collagen deposition. Targeting of P2X7R war-
rants further investigation as a promising therapeutic approach in pancreatic cancer.
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design qPCR primers speciﬁc for other than the isoform
A. For the Western blot, membranes were incubated with
primary antibody against P2X7R C-terminal (1:500 rabbit
polyclonal, Alomone, APR-004).
SiRNA transfection
PancTu-1 Luc cells were transfected with 50 nM siRNA
against P2X7 mRNA (siP2X7) or siRNA Naito-1 (scramble)
as control (Tebu-Bio, Roskilde, Denmark), using Lipofect-
amine RNAiMAX (Invitrogen). Experiments were performed
48 hr after transfection.
Cell proliferation and migration
Cell proliferation and wound assays were performed according
to the procedures described earlier.24 Aphidicolin (5 mM) was
used to stop proliferation.
Mouse pancreatic stellate cells (mPSCs) isolation
Animals were handled according to the guidelines by the Dan-
ish Animal Experimentation Inspectorate (license no. 2011/
561-56). Male Balb/cJ P2X7 wild type mice (Taconic) and Balb/
cJ P2X72/2 mice27 were used for PSC isolation as described
earlier25 with the following modiﬁcations: excised pancreas was
washed in cold Gey’s Balanced Salt Solution (GBSS), suspended
in 3 ml of cold GBSS containing 3 mg of Collagenase P (Roche)
and cut into small pieces. The suspension was incubated at
378C for 30 min, then dispersed by pipetting and centrifuged at
1040 g for 8 min at room temperature. The supernatant was
removed and the pellet was re-suspended in warm culture
media (DMEM/F12 1:1, 10% FBS, 100 U/ml penicillin, 100 lg/
ml streptomycin) and transferred to a Petri dish precoated with
pure FBS. After 2 hr of incubation at 378C in 5% CO2, the
media was removed and the dish was washed several times.
PSCs remained attached to the bottom of the dish.
Co-culture of mPSCs and PancTu-1 Luc cells
Wild type or P2X72/2 mPSCs (30.000; passage 1–3) were plat-
ed in a 24-well plates. After 24 hr PancTu-1 Luc cells (50.000)
were plated in the upper chamber of the insert (transparent
PET membrane, 8.0 lm pore size, Falcon) with 5 mM Aphidico-
lin and either with or without AZ10606120 (10 mM). After 48
hr, cells were ﬁxed in cold methanol and stained with Crystal
Violet. Bright ﬁeld images were taken with 10x objective in
Leica DMI6000B microscope. Cells were counted using ImageJ
(version 1.47, National Institute of Health, Bethesda, MD).
Orthotopic PancTu-1 Luc pancreatic tumour mouse model
This study was approved by the administration of Lower Saxo-
ny (Germany) and animals were handled according to the
guidelines issued by the animal protection (licence no. 33.9–
42502-04–13/1085). Experiments were performed on 10–19
weeks old male athymic nude mice (NMRI-Foxn1nu) bred in
the Animal Facility of the University Medical Center G€ottingen.
Animals were housed in individual-ventilated cages (IVS) and
allowed food and water ad libitum. For orthotopic
transplantation, mice were anesthetized by intraperitoneal (i.p.)
injection of 15 mg=kg xylazine and 75 mg=kg ketamine.
PancTu-1 Luc cells grown in media without antibiotics were
harvested with 0.25% trypsin-EDTA solution and washed twice
with medium. The 1 3 106 cells were re-suspended in 20 ll of
sterile PBS and injected in the head of the pancreas (Fig. 1a) as
previously described.28 Mice were weighed and inspected twice
a week for weight loss, general condition and tumour
formation.
Treatment schedule
Animals were randomly divided into two groups treated with
either 5 mg/kg AZ10606120 re-suspended in NaCl 0.9%
(1 mg/ml) (n5 7) or with NaCl 0.9% (n5 6) alone as vehicle
control (i.p. injection was performed every other day for both
treated and control groups). Treatment started 10 days after
implantation of cancer cells, and was continued every second
day until sacriﬁce on Day 30 (Fig. 1b).
Bioluminescence imaging
In order to assess primary tumour growth in vivo over time
in response to therapy, Bioluminescence imaging (BLI) meas-
urements were done at Day 10, 17, 23 and 30, and treatments
were started after the ﬁrst measurement at day 10. Mice were
injected i.p. with 50 mg/ml of D-luciferin (Promega) dis-
solved in sterile PBS at a dose of 150 mg/kg body weight.
Ten minutes after D-luciferin injection, mice were placed on
the stage of the IVIS-Spectrum (PerkinElmer) and imaged
with CCD using default bioluminescence settings of Living
Image 4.4 software (open ﬁlter conﬁguration, automatic
exposure time, F/Stop5 1) with medium binning. A sequence
of ﬁve images (segments) with a delay of 1 min each was
acquired. To quantify the in vivo signal intensity over time,
regions of interest (ROIs) encompassing the entire primary
tumour mass were placed on the 2D bioluminescence images
acquired 15 min (maximum intensity) after D-luciferin injec-
tion and total ﬂux (photon/sec) over this area were calculated.
At Day 30, mice were scanned again in vivo and then sacri-
ﬁced and scanned ex vivo with opened abdominal cavity by IVIS
Spectrum using the same parameters mentioned above. Immedi-
ately afterwards, the tumour together with the stomach and duo-
denum was removed and also scanned with BLI. Tumour sizes
were measured with caliper and volumes were calculated using
the formula: volume [mm3]5 0.53 (length 3 width3 height).
Grade of invasion into stomach and duodenum was macroscopi-
cally evaluated and the occurrence of ascites and jaundice, grade
of tumour invasion in the surroundings organs and size, num-
bers and location of metastases were recorded. Subsequently, ex
vivo bioluminescence imaging was performed on excised organs
such as spleen, liver, kidney, intestine and mesenteries to conﬁrm
the presence of metastases.
Immunohistochemistry and analysis of the stained tissues
Organs were placed in 10% buffered formalin and embedded
in parafﬁn for further histological evaluation. Slices (2 lm
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thick) were deparafﬁnized and rehydrated according to stan-
dard procedures, and pretreated at 988C for 20 min in citrate
buffer (pH 6.0, Dako). Slides were incubated for 10 min with
3% H2O2 or 0.1 M TRIS-glycine (pH 7.4) for chromogenic
and ﬂuorescent detection, respectively. Afterward, slides were
incubated with Protein Block (Dako) or Blocking Buffer–Fish
(SurModics) for 20 min to block unspeciﬁc protein binding.
Slides were incubated with the rabbit polyclonal antibody
anti-P2X7 C-terminus (Alomone APR-004, 1:200), or one of
the two rabbit anti-P2X7 extracellular loop antibodies (Alo-
mone APR-008, 1:200 or Life Technologies PA5-28020,
1:900), or the monoclonal rabbit anti-human EGFR (Life
Technologies MA5-16359, 1:100), or the polyclonal rabbit
anti-alpha smooth muscle actin (Abcam AB5694, 1:500).
Overnight incubation at 48C was followed by treatment with
N-Histoﬁne Simple Stain Max PO anti-rabbit (Nichirei) for 1
hr and staining with 3-Amino-9-ethylcarbazole (AEC). All
slides were counterstained with Mayer hematoxylin (Merck).
For the ﬂuorescence detection, the slides were incubated with
the relevant secondary antibody conjugated to Alexa Fluor-
568 or Alexa Fluor-488 (Life Technologies, 1:400) for 1 hr,
or directly incubated with the polyclonal antibody rabbit
anti-P2X7 receptor (extracellular)-ATTO-488 (Alomone
APR-008-AG, 1:400) overnight at 48C. DAPI (Molecular
Probes) was used for nuclear staining.
The collagen I/III and the connective tissue we detected
with the Picrosirius Red Stain Kit (24901, Polysciences) and
the Masson Goldner Trichrom Kit (12043, Morphisto),
respectively. After deparafﬁnization and rehydration, tissue
sections were stained with Weigert hematoxylin (Morphisto)
according to the manufacturer’s instructions. Bright ﬁeld and
immunoﬂuorescence pictures were taken in Leica DMI6000B
microscope and Leica SP 5X MP confocal laser scanning
microscope, respectively. Image J software was used to ana-
lyse the images. To quantify PSCs and collagen, slides were
stained for a-SMA and Picrosirius Red. Images (8–9 ﬁelds of
view per slide in each animal) were thresholded, converted
into binary images and the stained area was calculated.
Chemicals and statistics
All chemicals/kits were purchased from Sigma-Aldrich unless
otherwise stated. Data are shown as mean values6 standard
error of mean (SEM) and n represents the number of biologi-
cal replicates. Statistical analysis on data was performed by
using Students t test and one-way analysis of variance
(ANOVA) with Bonferroni method using SigmaPlot 11.0.
Data were analyzed in Origin or Microsoft Excel.
Results
PancTu-1 Luc cells express P2X7R
In order to use the human PancTu-1 Luc pancreatic cancer
cells in the orthotopic xenograft mouse model, we ﬁrst deter-
mined whether cells express P2X7R and investigated their
behavior in an in vitro setting, similar to our studies on other
PDAC cells.24 HPDE cells were used as control. Transcripts
for P2X7 in HPDE and PancTu-1 Luc cells were detected by
Figure 1. Orthotopic implantation of PancTu-1 Luc cells and timeline of AZ10606120 therapy. (a) PancTu-1 Luc cells injection in the head
of pancreas of a nude mouse at day 0. (b) Schematic diagram of the experimental protocol used for the treatment with AZ10606120 and
for the bioluminescence analysis. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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RT-PCR (Fig. 2a). Western blot analysis using an antibody
against P2X7R C-terminus (Fig. 2b) shows that both cell lines
express the full length P2X7R isoform (70 kDa). Notably,
PancTu-1 Luc cells showed a higher protein level compared
to the HPDE control cells.
Role of P2X7R in cell proliferation
Effect of ATP stimulation on proliferation of PancTu-1 Luc
cells was determined using BrdU assay (Fig. 2c; black bars).
There was a signiﬁcant reduction of about 20% in BrdU incor-
poration already with 10 lM ATP compared to the control (no
exogenous ATP). With 100 lM ATP this reduction became
more pronounced (about 80%), and it remained similar with
1 mM ATP. The treatment with allosteric P2X7R inhibitor
AZ10606120 (10 lM; Fig. 2c, white bars) reduced BrdU
incorporation (80%) at both basal conditions and at low ATP
concentrations (0 or 10 lM). This effect was most likely due to
an arrest of proliferation, since AZ10606120 is not cytotoxic at
10 lM concentration.29 Moreover, the inhibitor in combination
with higher ATP concentrations (100 lM to 1 mM) further
reduced BrdU incorporation, due to a stop of proliferation
caused by the inhibitor and potentially due to cell death
induced by high ATP concentrations, similar to effects detected
on other PDAC cells.24 We also used BzATP, which is often
used to stimulate P2X7R, though some reports claim activation
of other P2 receptors.24,30 The reduction in BrdU incorporation
became apparent at 100 lM and 1 mM of BzATP, (Fig. 2d). In
order to conﬁrm that P2X7R is involved in cell survival, we per-
formed studies where the receptor was silenced using siRNA.
Results in Figures 2e–2f show that knockdown of the receptor
caused decreased BrdU incorporation indicating reduced pro-
liferation. Addition of BzATP (100 lM), which would have
reduced BrdU incorporation in control conditions, lost its
effect in cells treated with siRNA.
mPSCs stimulate PancTu-1 Luc cell
migration—role of P2X7R
To evaluate the role of P2X7R in PancTu-1 Luc cell migration
(Figs. 3a–3c), we performed a wound assay using removable
inserts to minimize cell damage and ATP release. Cells were
incubated either with AZ10606120, BzATP or both. PancTu-1
Luc cells closed almost 65% of the wound/gap after 30 hr.
BzATP increased cell migration (Fig. 3b) and the wound/gap
was near closure within 30 hr (Fig. 3c). In contrast,
AZ10606120 drastically reduced cell migration and abolished
BzATP effect; at the end point almost 70–80% of the wound
Figure 2. Expression of P2X7R and cell proliferation with ATP,
AZ10606120 and BzATP. (a) Representative gel of P2X7mRNA
expression (284 bp) in HPDE (H) and PancTu-1 Luc (P) cells (n53).
(b) Western blot on the whole cell lysates with polyclonal C-terminal
antibody for P2X7R shows the A isoform (70 kDa). b actin (42 kDa)
was used as loading control (n54). Bar graph shows the level of
P2X7R protein as a ratio to b actin. Significant difference in compari-
son to HPDE cells p<0.001 (**) is reported. (c) Effect of ATP and ATP
plus AZ10606120 on PancTu-1 Luc cell proliferation was assayed
using BrdU incorporation. Black bars show the effect of increasing
concentration of exogenous ATP (0 lM, 10 lM, 100 lM and 1 mM).
White bars represent the effect of increasing ATP concentration in
combination with 10 lM AZ10606120 (P2X7R allosteric inhibitor).
(d) Effect of increasing concentrations of BzATP (P2X7R agonist) on
BrdU incorporation. Each run was performed in triplicates and the
graphs show data from four independent experiments (mean6SEM).
Significant differences p<0.05 (*, #) and p<0.001 (**, ##) from the
respective control, without exogenous ATP or BzATP (*, **) and with/
without inhibitor (#, ##) are indicated. (e) The graph shows PancTu-1
Luc cell proliferation after transfection with siRNA against P2X7
mRNA (siP2X7), scramble siRNA (siSCR) and siP2X7 plus BzATP (100
lM). Data are represented as mean6SEM. Significant differences
p<0.001 (**) from the control are indicated. (f) Western blot shows
the protein expression of P2X7R in PancTu-1 Luc cells transfected
with siRNA against P2X7R (siP2X7) or scramble Naito-1 siRNA as con-
trol (siSCR).
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Figure 3. Effect of AZ10606120, BzATP and mPSCs on PancTu-1 Luc cells migration. PancTu-1 Luc cells were grown to confluence in the
two-chamber silicon insert. After removal, phase-contrast images were taken every hour for 30 hr. (a) Representative images at 0, 15 and
30 hr for control, AZ10606120, BzATP and P2X7R inhibitor plus BzATP. (b) White, black, grey and light grey circles show the percentage of
the wound/gap open every hour in control cells (vehicle); cells treated with 10 lM AZ10606120, with 10 lM BzATP and AZ10606120 plus
BzATP, respectively. Significant differences p<0.05 (*) between control and inhibitor/agonist was calculated from the slope of the curves
after 11 hr. (c) The graph shows the endpoint, i.e., percentage of wound still open after 30 hr; significant differences p<0.05 (*) and
p0.001 (**) are indicated. Four to seven fields of view were analyzed per each experiment. The graphs show data from 3 to 4 indepen-
dent experiments (mean6SEM). (d) The graph shows effect of mPSCs from wild-type and P2X7 knockout (1/2AZ10606120) on PancTu-1
Luc cells migration. The graph shows data from four independent experiments (mean6SEM). Significant differences p<0.001 (**) are
indicated.
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was still open (Fig. 3c). These results suggest that P2X7R is ton-
ically active and involved in basal cell migration.
To determine if P2X7R plays any role in PSCs-cancer cells
crosstalk, we performed Boyden chamber experiment, in which
PancTu-1 Luc cells were co-cultured (upper chamber) with
freshly isolated mPSCs (lower chamber) (Fig. 3d). We observed
a remarkable increase in PancTu-1 Luc cell migration when
they were stimulated by mPSCs expressing wild type P2X7R.
However, when we used mPSCs isolated from P2X7-/- mice in
the lower chamber, cancer cell migration was signiﬁcantly
reduced, and AZ10606120 had no further effects. This indicates
that PSCs release chemotactic factors which attract cancer cells
and that P2X7R plays a role in their secretion.
PancTu-1 Luc orthotopic mouse tumour model—
characterization and P2X7R expression
The next objective was to conﬁrm our in vitro ﬁndings on an
in vivo cancer model. A PancTu-1 orthotopic xenograft mod-
el has been chosen for the study, similar as the one already
established and characterized by Alves et al.,28 as it reﬂects
invasion and all the steps of the metastatic cascade of human
PDAC. Since one of the disadvantages of an orthotopic
PDAC model is the difﬁculty of following tumour growth
and spread, the implanted luciferase-expressing PancTu-1
Luc cells allowed noninvasive bioluminescence imaging (BLI).
PancTu-1 Luc cells were implanted in the head of the pan-
creas of athymic nude mice (Fig. 1a) and an extensive local
tumour growth (n5 4, tumour take5 100%) already within 4
weeks after implantation was observed. In ﬁxed tissue,
tumour cells were visualized by staining for epidermal growth
factor receptor (EGFR), a receptor that is over-expressed in
PDAC.31 PancTu-1 Luc cells formed poorly differentiated,
highly EGFR-expressing tumours (Supporting Information
Fig. 1a). The PancTu-1 Luc showed very aggressive tumour
growth, frequently invading into the surrounding organs,
such as duodenum and stomach (Supporting Information
Fig. 1b) as well as the mesentery, spleen, kidney and liver
(Supporting Information Figs. 1c–1f).
To validate the expression level of P2X7R in PancTu-1
Luc primary tumours and in surrounding pancreas, tissues
were stained with P2X7R-targetting antibody. Additionally,
consecutive sections were stained with antibody-targeting
human EGFR, and with antibody targeting a-SMA expressed
in mPSCs (Fig. 4a). The images show that between cancer
cells there are dense areas populated by mPSCs. mPSCs and
luminal membranes of pancreatic ducts express P2X7R. Next
we stained the tumour and pancreatic sections with three
different antibodies against P2X7R, which have different spe-
ciﬁcities for murine and human tissue, and potentially recog-
nize different receptor isoforms (Figs. 4b–4d). With the two
murine antibodies, directed against extracellular domain (all
P2X7 splice isoforms; Fig. 4b) and C-terminal (nontruncated
isoforms; Fig. 4c), the P2X7R was found in the PanIN struc-
tures, and in acinar-like structures with increased lumen size
and/or small ducts, which would indicate acinar-to-ductal
metaplasia. Furthermore, mPSCs stained heavily with both
antibodies. The P2X7R expression in PancTu-1 Luc tumour
cells was veriﬁed with the anti-P2X7R human antibody
(PA5-28020-C-term) optimized for parafﬁn section and
images show heavy expression in the tumour cells (Fig. 4d).
The tumour-free pancreas (Fig. 4e) shows that P2X7R is
expressed in pancreatic ducts, mPSCs and islets of Langer-
hans, but not in pancreatic acini, which agrees with earlier
studies.25,32,33 Similar staining was obtained in normal pan-
creas using immunoﬂuorescence (data not shown).
Effect of P2X7R inhibitor AZ10606120 on tumour growth
Having established that P2X7R is expressed in the tumour
niche, the next objective was to determine whether the receptor
inhibitor AZ10606120 would inﬂuence the growth and spread
of pancreatic cancer. Therapy regime, shown in Figure 1b, was
started at Day 10 after cells implantation. The tumour progres-
sion was assessed by BLI. The bioluminescence was acquired
before the start of the therapy as well as at Day 17, 23 and 30
postimplantation. In all mice, BLI over primary tumour area
increased over time, but the treated mice revealed a reduced
increment of the signal intensity compared to the nontreated
group, as shown on the representative images in Figure 5a. The
animals showed widely different BLI at day 10. In order to
quantify these results, the total ﬂux (photons/sec) over primary
tumour area was measured using 2D ROIs, normalized to the
total ﬂux at Day 10 for each mouse and log-transformed. As
shown in the Figure 5b, the control NaCl-treated group showed
steeper progression in BLI with time, compared to the group
treated with P2X7R allosteric inhibitor, AZ10606120. This sug-
gests faster tumour growth, and/or higher metabolic activity of
the tumour cells in the nontreated animals. AZ10606120 inhibi-
tor had no effect on luciferin/luciferase assay in vitro (data not
shown).
At Day 30 after the implantation mice were sacriﬁced. Ex
vivo bioluminescence imaging of animals with opened
abdominal cavity and explanted primary tumours conﬁrmed
the detection of luminescence signals over primary tumour
mass (Supporting Information Figs. 2a and 2b). The tumour
sizes were also measured ex vivo with caliper. Here no signiﬁ-
cant differences in the average tumour volume between
treated and untreated group were detected (Supporting Infor-
mation Fig. 3a); but the tumours of untreated mice showed
clearly higher deviation. The difference in the results between
in vivo BLI (signiﬁcantly lower luminescence intensity in the
treated group) and the tumour volume measurement during
the section (no signiﬁcant difference between the groups) can
be explained with the fact that apparently, most of the mice
randomly chosen for treatment had bigger tumour mass at
the beginning of the therapy at the Day 10 than the mice
chosen as controls (Supporting Information Fig. 3b). The
normalization of the imaging data for BLI at beginning of
the therapy corresponds to the actual progression of the
primary tumour and implicates the reduction in the tumour
size with the inhibitor.
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Figure 4. P2X7R expression in PancTu-1 Luc in vivomodel. (a) Immunofluorescence detection of EGFR in the tumour cells (red), a-SMA for the pan-
creatic stellate cells (cyan) and P2X7R (ATTO-488, green). The staining was performed in two subsequent 2 mm sections. (b–d) Representative pic-
tures of P2X7R expression in PancTu-1 Luc tumour paraffin sections. The slides were stained with three different P2X7R antibodies: (b) APR-008
against an epitope in the extracellular loop. (c) APR-004 against the C-terminal; (d) PA5-28020 against the C-terminal and more specific for human
tissues embedded in paraffin. (e) Control of P2X7R antibody (PA5-28020) in a tumour-free pancreas of the PDAC mice. In images (b–d) following
structures are indicated: Islets of Langerhans (a), ducts (b), PanINs (c) and acinar-like structures with increased lumen size (arrows). All images are
representative of staining carried out on n53–6. Images were taken with different magnifications but scale bars are 50 mm on all panels. [Color fig-
ure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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Incidence of metastases was determined during the section
macroscopically and by bioluminescence imaging of further
extracted organs such as mesentery, spleen, liver and kidney
(Supporting Information Fig. 2c). Both treated and untreated
groups showed a frequent and comparable disseminated pat-
tern with visible metastases in those organs. Data given in
the Supporting Information Figure 2d show that there was no
clear difference between the two groups, indicating that P2X7R
allosteric inhibitor alone is not efﬁcient in blocking the meta-
static and invasive behavior of PancTu-1 Luc cells in vivo.
Tumour inﬁltration in the surrounding organs such as
stomach and duodenum was determined by EGFR staining
Figure 5. Effect of AZ10606120 on tumour growth.(a) In vivo representative bioluminescence images obtained by IVIS Spectrum of PancTu-1
Luc mice treated either with 0.9% NaCl (upper panel, n56) or with AZ10606120 (lower panel, n57) at day 10, 17, 23 and 30 after cells
implantation. Bioluminescence signals detected 15 min after the i.p. injection of luciferin over tumour areas of the nontreated mice increased
faster than in the treated group. The given images and a scale is depicting radiance at day 30 to avoid oversaturation. (b) The graph shows
the radiances (photons/second) measured over primary tumours using 2D ROIs at the indicated days after cells implantation normalized to
the total flux at day 10 for each mouse (mean6SD). The black symbols represent the tumour growth of the mice treated with NaCl (n54)
and the white symbols the tumour growth of the mice treated with AZ10606120 (n54). Progression of BLI over time indicated significant dif-
ference between NaCl and inhibitor-treated mice (p<0.05 (*) slope analysis), and point to point comparison between groups is significant at
day 23 and 30 (p<0.05). [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
M
ol
ec
ul
ar
C
an
ce
r
B
io
lo
gy
2548 Targeting of the P2X7 receptor in pancreatic cancer and stellate cells
Int. J. Cancer: 139, 2540–2552 (2016) VC 2016 The Authors International Journal of Cancer published by John Wiley & Sons Ltd on behalf of
UICC
of tumour sections (Supporting Information Fig. 4). No dif-
ferences were observed between the two groups.
P2X7R inhibition reduces fibrosis and mPSC number
In order to evaluate whether there was any effect of the P2X7R inhi-
bition on the ﬁbrotic area and on mPSCs, immunohistochemistry
and immunoﬂuorescence studies were performed on the
tumour slices. Analysis of the tumour ﬁbrosis, using Masson
Goldner trichrome staining for connective tissue (Fig. 6a)
revealed a denser ﬁbrosis in untreated mice compared to
treated ones. Additional analysis of the ﬁbrosis composition
using Picrosirius Red staining for collagen I and III (Figs. 6b–
6c), showed that the treatment with P2X7R allosteric inhibitor
caused a reduction in collagen production/deposition, visible
also in a more loose structure of collagen ﬁbres and lower
intensity staining (Fig. 6b). This was further quantiﬁed as
stained areas using Image J (Fig. 6c) and data show that
AZ10606120 clearly and signiﬁcantly reduced the tumour
ﬁbrosis.
It is well known that PSCs are the principal source of
collagen in the stroma in response to pancreatic injury.34
Moreover, in a previous study, our group showed that the
P2X7R allosteric inhibitor AZ10606120 considerably reduced
in vitro mPSCs proliferation.25 Therefore, to understand if
the reduction in collagen deposition was related to the
reduced number and/or activity of mPSCs, we stained the
tumour sections with a-SMA antibody. Immunohistochemi-
cal images (Fig. 6d) show denser a-SMA in tumours of con-
trol animals. In order to quantify mPSCs staining, we used
immunoﬂuorescence imaging (Fig. 6e) and quantiﬁed the
area occupied by mPSCs. The data presented in Figure 6f
clearly show that treatment of the mice with AZ10606120
Figure 6. Effect of AZ10606120 on mPSCs and collagen deposition.Representative pictures of Masson Goldner Trichrom (a) and Picrosirius
Red (b) staining of treated and untreated PancTu-1 Luc tumours. (c) The graph shows the difference in collagen deposition (stained area)
between the NaCl and AZ10606120 groups. The staining was performed in all tumours (n56–7) and eight to nine fields of view were
analyzed in each slide (see Methods). Significant difference p<0.05 (*) is indicated. (d) Representative pictures of AEC reaction and
immunofluorescence (e) for pancreatic stellate cells detection, using an antibody against a-SMA. (f) The graph shows the results of the
stained area analysis of the a-SMA immunofluorescence staining in treated and untreated groups (mean6SEM). Eight to nine fields of
view, per each tumour section, were analyzed. Significant difference p<0.05 (*) between NaCl and AZ10606120 mice is indicated.
Different magnifications were used on right and left images in panels A and D but scale bars are all 50 mm, also in panels B and E. [Color
figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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resulted in the reduction of the area covered by mPSCs, indi-
cating possibly lower number or less active cells.
Discussion
In this study we showed that P2X7R regulates proliferation
of PancTu-1 Luc cancer cells in vitro and promotes the
migration of PancTu-1 Luc under mPSCs stimuli. We also
demonstrated that these functions could be inhibited by the
P2X7R inhibitor AZ10606120 in vitro. Based on these ﬁnd-
ings, we evaluated the efﬁcacy of AZ10606120 on PancTu-1
Luc orthotopic pancreatic tumour-bearing mice using in vivo
bioluminescence imaging to monitor PDAC growth and
spread. We demonstrated that P2X7R is expressed in primary
tumour cells and in mPSCs and that AZ10606120 decreases
tumour bioluminescence as well as mPSCs cell activity/num-
ber and collagen deposition. However, treatment of mice
with the inhibitor had no effect on tumour invasion and
spread to the other organs.
The P2X7 receptor is expressed in PancTu-1 Luc at the
mRNA and protein levels (Figs. 2a and b), and the protein
expression is higher in the tumour cells compared to HPDE
cells. This ﬁnding agrees with our previous study on the
receptor expression in other PDAC cell lines,24 and with sev-
eral studies performed on different cancer types, e.g., breast
cancer, nonsmall cell lung cancer35 and melanoma.36 In our
study, stimulation of PancTu-1 Luc with increasing exoge-
nous concentrations of ATP or BzATP decreased cell prolif-
eration/survival, similar to other PDAC cell lines and reports
on other cancer cells.24,29,37 The allosteric inhibitor of P2X7R,
AZ10606120, signiﬁcantly reduced BrdU incorporation, due
to an arrest of cell proliferation. The inhibitor was effective
even without exogenous ATP, and presuming that the inhibi-
tor is speciﬁc, it implicates that the receptor was tonically/
basally active in our PDAC cell model. These conclusions
were supported by experiments with siRNA. Similar effect of
P2X7R on cell survival and effects of the allosteric inhibition
of P2X7R were also shown on mouse pancreatic stellate
cells,25 ovarian carcinoma cells38 and in vivo on melanoma
cancer model.20
An important characteristic that makes PDAC aggressive
is the ability of tumour cells to migrate and invade the sur-
rounding or distant tissues. Here, we demonstrated that can-
cer cells migration was increased in vitro by P2X7R
stimulation and inhibited by AZ10606120 (Figs 3a–3c). Our
data are in line with other studies showing the role of P2X7R
in migration in breast cancer cells,18,39 lung cancer cells40
and prostate cancer cells.41 In stroma-rich PDAC interplay
between cancer cells and PSCs, which has been termed as the
“deadly symbiosis”, leads to a massive cancer cell migration
and invasion.42 Here, we showed that P2X7R is important in
enhancing cancer cell migration and/or chemotactic factor
release suggesting interaction between PDACs and PSCs (Fig.
3d).
In vivo, the implanted PancTu-1 Luc primary tumours
clearly expressed P2X7R (Fig. 4). The luciferase activity
allowed us to follow the tumour growth by detecting the bio-
luminescent signal after i.p. luciferin injection. It appears that
the group of tumour-bearing mice treated with AZ10606120
showed a lower increase in bioluminescence over time com-
pared to mice that received the vehicle. This validates that
the P2X7R allosteric inhibitor AZ10606120 has anti-
proliferative effects both in vitro and in vivo. This inhibitor is
not yet widely tested in cancer, but two studies show that
similar anti-proliferative effect of the inhibitor was detected
in subcutaneous cancer induced by HEK293-hP2X7 or B16
melanoma cells.1,20
We found P2X7R expressed in pancreatic ducts and PSCs,
and islets of Langerhans, as expected from other expression
and functional studies of normal pancreas.25,32,33,43 There was
a signiﬁcant increase in PanIN structures that were heavily
stained with P2X7R antibody in tumour vicinity. Interesting-
ly, acinar-like structures with increased lumen size, in/close
to the tumour mass, showed heavy expression of P2X7R.
Notably, normal rodent acini do not express P2X7R on the
protein level (Fig. 4) or on mRNA level or functional level.44
This implies that implantation of human cancer cells induces
P2X7R overexpression in murine pancreatic tissue of epitheli-
al origin: ductal neoplasia and acinar-to-duct metaplasia.
Pancreatic stellate cells play an important role in this des-
moplastic reaction by synthetizing a large amount of extracel-
lular matrix proteins, such as collagens.8 Here we show that
administration of P2X7R inhibitor reduced the number or
activity of mPSCs and this correlated with a reduction of col-
lagen deposition (Figs. 6b–6f) resulting in a less rigid stromal
reaction. These ﬁndings correlated also with the high expres-
sion of P2X7R in mPSCs showed in Figures 4a–4d and with
the in vitro anti-proliferative effect of AZ10606120 on mPSCs
showed in our previous study.25 Nevertheless, at this stage
more basic knowledge regarding targeting of PSCs and des-
moplasia is needed. Recent publication in PDAC research
question whether inhibition of stroma and ﬁbrosis is advan-
tageous as, on one hand, it may improve the drug delivery
but, on the other hand, it may remove restrain on tumour
growth and metastasis.45–47
The P2X7 receptor is a therapeutic target not only in can-
cer but in several diseases, such as rheumatoid arthritis, Alz-
heimer’s disease, respiratory diseases and renal diseases,48,49
and several P2X7R inhibitors are currently in phase I and II
of clinical trials.48 AZ10606120 was not yet so widely used,
except in a couple of subcutaneous cancer models.1,20 Our
application to the PDAC orthotopic model indicates relatively
high efﬁcacy (i.p. 5 mg/kg) in inhibiting both mPSCs as well
as PDAC cells compared to other P2X7R inhibitors.50
In vivo we could not show any signiﬁcant effects of the
inhibitor on invasion and metastasis development, although
in vitro we have seen clear effects of the inhibitor on
PancTu-1 Luc cell migration. It is possible that, despite of
the high P2X7R over-expression of PancTu-1 Luc cells, the
invasion and metastatic behavior of the undifferentiated
tumours formed by these cells in vivo is too aggressive to be
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blocked only by this inhibitor alone. In this context, a less
aggressive and more differentiated P2X7R over-expressing
PDAC mouse model could be more useful, such as Capan-1
or Capan-2 xenografts, which become clinically symptomatic
in about 90 days after cell injection,31 as compared to 30
days needed by the PancTu-1 Luc cells. Furthermore, we
might need to consider polymorphisms of the P2X7 receptor
and heterogeneity of cancer cells. For example, tumours
might contain both pro-apoptotic/necrotic P2X7R isoforms
(or SNPs) as well as trophic receptor variants that support
growth and metastasis. Lastly, as discussed above, conse-
quences of targeting of tumour-stroma may have complex
outcomes.
Conclusion
In conclusion, our work shows that P2X7R plays an impor-
tant role in several aspects of in vivo and in vitro PDAC pro-
gression. Therefore, P2X7R inhibition might decrease
pancreatic cancer aggressiveness, acting on multiple fronts—
PDAC proliferation, interaction of cancer cells and PSCs,
PSCs viability and collagen deposition. The AZ10606120
anti-proliferative effect on cancer cells and the reduction of
pancreatic cancer-associated ﬁbrosis could open a new possi-
bility for pancreatic cancer treatment co-targeting cells in the
pancreatic tumour microenvironment. In order to proceed in
this direction more reﬁned P2X7R models, including immune
systems, are needed as well more thorough understanding of
the role of this receptor in stroma-tumour interaction and
metastasis.
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